---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-035847"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2025-07-24T23:59:59+00:00"
generated_at: "2026-05-18T02:24:56.189129+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vir doses first patient in Phase 1 trial of EGFR-TCE VIR-5525; triggers $75M milestone payment to Sanofi

## Summary
- First patient dosed in Phase 1 trial of VIR-5525, a dual-masked T-cell engager targeting EGFR, in solid tumors (NSCLC, CRC, HNSCC, cSCC).
- Dosing triggers a $75M milestone payment to Sanofi under the 2024 license agreement, recognized as R&D expense in Q3 2025.
- $75M milestone was held as restricted cash and excluded from the $1.02B cash reported as of March 31, 2025.
- Dose escalation continues for TCEs VIR-5818 (HER2) and VIR-5500 (PSMA) in heavily pretreated patients, showing early response signals.
- VIR-5525 is Vir's third dual-masked TCE in clinical trials; preclinical candidates integrating PRO-XTEN and AI discovery are advancing.

## SEC filing metadata
- accession: 0001628280-25-035847
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2025-07-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000162828025035847/0001628280-25-035847-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000162828025035847/vir-20250724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-035847
- JSON: https://secwatch.observer/filing/0001628280-25-035847.json
- Plain text: https://secwatch.observer/filing/0001628280-25-035847.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.